Quest Diagnostics Incorporated (DGX) — BATS 42/100 — 2026-07-23

Listen to the earnings call audio for free on StockAnalysis

Summary based on Quest Diagnostics Incorporated earnings call on 2026-07-23

BotFlo AI Transformation Score for $DGX: 42 (42/100)

Sector AI Transformation Score for $DGX: 11 (11/50)

Presentation

(1/5) Q2 2026 strong growth and raised guidance
• 📈 Second-quarter revenues grew over 10% with adjusted diluted EPS up over 19% on broad clinical demand and collaboration volumes.
• 🤖 Automation and AI across the business are driving continuous quality and productivity gains in and outside the labs.
• 📊 Strategic execution plus demographic and technology trends support another full-year guidance raise.

(2/5) Physician, hospital, and consumer channel execution
• 🏥 Physician-channel revenue grew high single digits on clinical innovations, new wins, and enterprise prevention and wellness accounts.
• 🤝 Hospital revenues grew double digits primarily from Corewell Co-Lab Solutions, with a new California nonprofit Co-Lab agreement added.
• 🧬 Consumer health and questhealth.com delivered robust wellness-panel growth while advanced diagnostics grew double digits in several clinical areas.

(3/5) Oncology milestones for Haystack MRD
• ✅ New York State approved Haystack MRD, enabling commercial efforts in all 50 states after rigorous quality review.
• 🔗 Quest became the largest reference lab to extend cancer tests such as Haystack MRD through Flatiron Health OncoEMR molecular profiling integration.
• 🚀 A pilot with American Oncology Network began, with planned rollout to Flatiron's 4,700 clinicians later this year.

(4/5) Operational excellence, AI, and automation investments
• 💰 Invigorate remains on track to deliver 3% annual cost savings and productivity improvements.
• 🔬 The Hologic Genius digital diagnostic system uses AI to scan digitized Pap slides for cervical cancer signs and was installed in two more lab locations.
• 🛠️ IntelliDraw launched to guide physician specimen collection, and an AI tool will cut PSC supply tracking and ordering time this year.

(5/5) Financial results and updated 2026 outlook
• 💵 Consolidated revenues were $3.04 billion, up 10.2%, with DIS organic growth of 10.1% and total volume up 13.1%.
• 📉 Adjusted operating margin was 16.5%, down versus prior year after Nova, Corewell ramp, and deferred-compensation headwinds totaling about 70 basis points.
• 📈 Full-year guidance was raised to revenues of $11.95–$12.05 billion and adjusted EPS of $11.05–$11.25, with about $1.8 billion operating cash flow.

Q&A

(1/14) Q&A: Hospital channel growth, Co-Lab pipeline, and bad debt
• 🏥 Total hospital portfolio growth was driven mainly by Corewell, while core reference and ex-Corewell Co-Lab same-store growth were mid-single digits with no slowdown.
• ✅ Bad debt is not a concern for hospitals or client bills, with no adverse bad-debt trends observed.
• 🤝 A new California regional hospital supply-chain relationship was added and the remaining-year funnel looks good.

(2/14) Q&A: ACA and Medicaid headwind versus guidance
• 📊 Full-year guidance still embeds a 30 basis-point revenue impact from ACA exchange subsidy changes.
• 📉 Exchange req volume is down about 8% but tests per req are up about 6%, leaving tests only about 2% lower and revenue roughly flat on mix.
• ⚠️ A worse back-half impact is possible, but a major business hit is not currently visible.

(3/14) Q&A: Second-half margin ramp versus Nova and fuel costs
• 📉 Q2 adjusted operating margin of 16.5% was down 40 bps, with about 70 bps of headwinds from Nova, Corewell/Fresenius, and SDCP mark-to-market.
• ⛽ Back-half headwinds include fuel costs near the high end of the prior ~$10 million range and Nova spend rising to about 70% of full-year outlays.
• 📈 Offsets are continued volume strength and lapping Corewell/Fresenius dilution in Q4, supporting full-year operating margin expansion.

(4/14) Q&A: Corewell outlook, pricing, and Fresenius margin lift
• 💵 Corewell remains about a $250 million full-year revenue contribution with low- to mid-single-digit margins progressing as expected toward a JV early next year.
• 🏷️ Company pricing expectations remain roughly flattish year-over-year, with slight health-plan positivity and slight hospital-reference negativity.
• 📈 Fresenius adds nearly $100 million of year-over-year revenue with improving margins that support second-half operating margin.

(5/14) Q&A: Bad debt percentage, collections, and patient concessions
• ✅ Bad debt remains in line with expectations and prior periods, with no meaningful deterioration in hospital collection rates or timing.
• 💳 Patient concessions hover around 5% of revenues and slightly improved versus the prior-year quarter.
• 🔒 Controls include poverty-based sliding scales, agency placements, and requiring significant past-due balances to be paid before new PSC services.

(6/14) Q&A: Why DSOs rose year-over-year and sequentially
• 📅 One minor DSO driver was a technical difference in deposit days that does not reflect receivable performance.
• 🛒 Business mix shifted toward client-bill and consumer revenues that have longer collection periods than health-plan third-party payers.
• 📊 Management characterizes the DSO move as a revenue-mix nuance rather than a collections problem.

(7/14) Q&A: PAMA outcomes and RESULTS Act strategy
• ⚖️ Three PAMA paths are CMS data collection potentially yielding January 1 rates, passage of the RESULTS Act, or another delay if RESULTS fails.
• 🏛️ RESULTS has broad bipartisan support with over 115 cosponsors and would use third-party adjudicated claims to set fairer market rates.
• ⚠️ Prior PAMA cuts overshot original savings estimates, supporting continued push for RESULTS or delay because original cuts were not sustainable.

(8/14) Q&A: Hospital deal pipeline amid ACA pressures
• 🔬 Reference outsourcing may be rising as hospitals send out tests they cannot profitably perform, and that book grew nicely in Q2.
• 🤝 Co-Lab and outreach funnels remain good after closing one Q2 arrangement, with preference for growing health systems.
• 📍 Quest also targets markets where its presence is weaker to gain local footholds through closer hospital relationships.

(9/14) Q&A: Drivers and sustainability of revenue per requisition
• 📈 Ex-Corewell/Fresenius mix, revenue per requisition rose 2.9%, led primarily by rising tests per requisition now almost north of 4.5 versus 3.5–4 pre-COVID.
• 🧪 High-value consumer wellness panels and advanced diagnostics or esoteric mix also lift revenue per requisition.
• 🧠 Brain health, advanced cardiometabolic, and autoimmune analyzer testing continue robust growth and often appear together in functional-health and chronic-care settings.

(10/14) Q&A: Haystack volumes after NY approval and Flatiron partnership
• ✅ New York approval of tumor-informed Haystack is a rigorous quality signal and opens major New York cancer centers.
• 🔗 Flatiron integration, alongside Epic and Quest's portal, simplifies ordering and result tracking for a large national oncologist base.
• 🧭 Commercial investment and test growth are paced to reimbursement progress, including Novitas and a MolDx Medicare Advantage submission hoped for later this year.

(11/14) Q&A: Utilization backdrop and payer pricing tone
• 📊 Utilization remains strong across hospital reference, core physician high-single-digit growth, and consumer trending to the high end of the prior 20–30% growth view.
• 📅 Discrete second-half growth items include the ACA 30 bp headwind, lapping Corewell/Fresenius and Elevance wins, plus normal Q3 weather risk, while core utilization assumptions stay strong.
• 🏷️ Health-plan pricing renewals remain constructive and consistent with flattish pricing as payers value high-quality lower-cost testing.

(12/14) Q&A: Oncology partnerships, Shield, and Haystack evidence priorities
• 🚫 Quest does not comment on Shield volumes and only notes menu access and draw services paid by the partner.
• 📚 Haystack clinical evidence is solid in colorectal cancer with ongoing breast and lung studies still to read out.
• 🎯 Adoption strategy pairs clinical evidence with leading sensitivity and specificity performance, including parts-per-million detection claims.

(13/14) Q&A: Elevance Alzheimer biomarker coverage and book size
• 🧠 Elevance now reimburses pTau-217, a biomarker Quest offers, but not yet the AB42/40 amyloid marker that Quest pairs in its algorithmic panel.
• 💵 Medicare Advantage broadly reimburses these panels and most testing is in patients over age 60.
• 📈 Absolute Alzheimer testing revenue is not sized, but the book is growing in the high double digits.

(14/14) Q&A: Updated PAMA and RESULTS Act policy outlook
• 🗓️ CMS data collection ends July 31 with an expected quality and participation report in late September or early October after Quest already submitted.
• 📜 If RESULTS passes, rates stay flat for 2027–2028, 2027 data would be collected, and new rates would begin in 2029 with no more than 5% annual cuts.
• 🏛️ Absent RESULTS, another delay is possible after six prior delays, and Quest will keep pushing RESULTS even if CMS sets new rates from current data collection.